Vera Therapeutics price target raised to $78 from $73 at TD Cowen
TD Cowen raised the firm's price target on Vera Therapeutics to $78 from $73 and keeps a Buy rating on the shares. The firm noted Trutakna (atacicept 150mg SC) received FDA accelerated approval for IgAN today with a broad label and no restrictions on UPCR levels. 12month eGFR analysis, due in 3Q26, will support an sBLA